FDA approves guanfacine for AD/HD in children, adolescents.

The Philadelphia Business Journal (9/3, George) reported, “The Food and Drug Administration granted marketing approval Thursday to Shire for Intuniv [guanfacine], a nonstimulant treatment for attention-deficit/hyperactivity disorder in children and adolescents aged six to 17.” Shire “already has three other AD/HD treatments in the United States and two AD/HD medicines outside the United States.”  HealthDay (9/3, Roberts) reported that Shire said its “once-daily” medication, “to be available in one-to-four mg strengths, is expected on pharmacy shelves in November.” Reuters (9/4) also covers the story.

Read Full Post »